Table 2.
Clinicopathological features of tumors with determined HER2 mRNA levels
| All HER2-negative (n = 173) |
HER2-zero (n = 77) |
HER2-low (n = 96) |
p value | HER2-null H-score 0 (n = 41) |
HER2-ultralow H-score 1-120 (n = 36) |
p value | |
|---|---|---|---|---|---|---|---|
| Histological type (%) | |||||||
| IDC | 164 (94.8) | 71 (92.2) | 93 (96.9) | 0.55# | 38 (92.7) | 33 (91.7) | 0.83# |
| ILC | 6 (3.5) | 3 (3.9) | 3 (3.1) | 2 (4.9) | 1 (2.8) | ||
| Other | 3 (1.7) | 3 (3.9) | 0 (0) | 1 (2.4) | 2 (5.6) | ||
| Histological grade (%) | |||||||
| 1 | 2 (1.2) | 1 (1.3) | 1 (1.0) | 0.15# | 1 (2.4) | 0 (0) | 0.05# |
| 2 | 87 (50.3) | 33 (42.9) | 54 (56.3) | 13 (31.7) | 20 (55.6) | ||
| 3 | 84 (48.6) | 43 (55.8) | 41 (42.7) | 27 (65.9) | 16 (44.4) | ||
| TNM staging group (%) | |||||||
| I | 4 (2.3) | 2 (2.6) | 2 (2.1) | 0.86# | 1 (2.4) | 1 (2.8) | 0.25# |
| II | 99 (57.2) | 42 (54.5) | 57 (59.4) | 19 (46.3) | 23 (63.9) | ||
| III | 70 (40.5) | 33 (42.9) | 37 (38.5) | 21 (51.2) | 12 (33.3) | ||
| Menopausal status (%) | |||||||
| Premenopausal | 76 (43.9) | 37 (48.1) | 39 (40.6) | 0.35# | 26 (63.4) | 11 (30.6) | 0.006# |
| Postmenopausal | 97 (56.1) | 40 (51.9) | 57 (59.4) | 15 (36.6) | 25 (69.4) | ||
| Hormone receptor (%) | |||||||
| Positive | 106 (63.0) | 44 (57.1) | 65 (67.7) | 0.16# | 16 (39.0) | 28 (77.8) | 0.001# |
| Negative | 64 (37.0) | 33 (42.9) | 31 (32.3) | 25 (61.0) | 8 (22.2) | ||
| H-score, median | 20 | 0.00 | 42.50 | < 0.0001* | 0.00 | 37.50 | < 0.0001* |
IC NOS, invasive carcinoma not-otherwise specified; TNM, tumor, node, metastasis; RCB, residual cancer burden
#Chi-square; *Mann-Whitney